{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20715920",
  "DateCompleted": {
    "Year": "2010",
    "Month": "12",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "31"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1586/erp.10.49"
    ],
    "Journal": {
      "ISSN": "1744-8379",
      "JournalIssue": {
        "Volume": "10",
        "Issue": "4",
        "PubDate": {
          "Year": "2010",
          "Month": "Aug"
        }
      },
      "Title": "Expert review of pharmacoeconomics & outcomes research",
      "ISOAbbreviation": "Expert Rev Pharmacoecon Outcomes Res"
    },
    "ArticleTitle": "Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.",
    "Pagination": {
      "StartPage": "441",
      "EndPage": "451",
      "MedlinePgn": "441-51"
    },
    "Abstract": {
      "AbstractText": [
        "Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA."
          }
        ],
        "LastName": "Hirsch",
        "ForeName": "Elizabeth B",
        "Initials": "EB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tam",
        "ForeName": "Vincent H",
        "Initials": "VH"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R15 AI089671",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R15 AI089671-01",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "1R15AI089671-01",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Pharmacoecon Outcomes Res",
    "NlmUniqueID": "101132257",
    "ISSNLinking": "1473-7167"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "economics",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Costs"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Drug Resistance, Multiple, Bacterial"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genotype"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Health Care Costs"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Length of Stay"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phenotype"
    },
    {
      "QualifierName": [
        "drug therapy",
        "economics",
        "microbiology",
        "mortality"
      ],
      "DescriptorName": "Pseudomonas Infections"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "Pseudomonas aeruginosa"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Failure"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virulence"
    }
  ]
}